ChiCTR2400084695 版本V1.0 版本创建时间2024/05/23 08:44:37 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400084695 

最近更新日期:

Date of Last Refreshed on:

2024-05-23 08:44:32 

注册时间:

Date of Registration:

2024-05-23 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

超声在痛风和高尿酸血症中的临床应用研究

Public title:

Clinical Application of Ultrasound in Gout and Hyperuricemia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

超声在痛风和高尿酸血症中的临床应用研究

Scientific title:

Clinical Application of Ultrasound in Gout and Hyperuricemia

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

邵勤 

研究负责人:

邵勤 

Applicant:

Qin Shao 

Study leader:

Qin Shao 

申请注册联系人电话:

Applicant telephone:

+86 23 6701 4942

研究负责人电话:

Study leader's
telephone:

+86 23 6701 4942

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

qinshao2011@126.com

研究负责人电子邮件:

Study leader's E-mail:

qinshao2011@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市江北区盘溪七支路6号

研究负责人通讯地址:

重庆市江北区盘溪七支路6号

Applicant address:

No.6, Panxi Seventh Branch Road, Jiangbei District, Chongqing

Study leader's address:

No.6, Panxi Seventh Branch Road, Jiangbei District, Chongqing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

重庆市中医院

Applicant's institution:

Chongqing Hospital of Traditional Chinese Medicine

研究负责人所在单位:

重庆市中医院

Affiliation of the Leader:

Chongqing Hospital of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2023-ky-11

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

重庆市中医院伦理委员会

Name of the ethic committee:

Ethics Committee of Chongqing Hospital of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2023-02-15 00:00:00

伦理委员会联系人:

魏知

Contact Name of the ethic committee:

Zhi Wei

伦理委员会联系地址:

重庆市江北区盘溪七支路6号

Contact Address of the ethic committee:

No.6, Pan Xi Qi Zhi Road, Jiang Bei District Chongqing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 23 6763 0637

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

重庆市中医院

Primary sponsor:

Chongqing Hospital of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

重庆市江北区盘溪七支路6号

Primary sponsor's address:

No.6, Panxi Seventh Branch Road, Jiangbei District, Chongqing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆市

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆市中医院

具体地址:

重庆市江北区盘溪七支路6号

Institution
hospital:

Chongqing Hospital of Traditional Chinese Medicine

Address:

No.6, Panxi Seventh Branch Road, Jiangbei District, Chongqing

经费或物资来源:

重庆市中医院

Source(s) of funding:

Chongqing Hospital of Traditional Chinese Medicine

研究疾病:

痛风,高尿酸血症  

Target disease:

gout, hyperuricemia

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

尝试自主开发痛风和高尿酸血症的肌骨超声半定量评分系统,为准确评估关节病变提供新的工具。应用肌骨超声形态学评估痛风和高尿酸血症患者体内尿酸负荷,为疾病诊断和降尿酸治疗提供依据,促进痛风诊断及降尿酸治疗的精准化和达标率。将肌骨超声充分应用于痛风和高尿酸血症患者全病程监测,提高诊断及治疗效率,构建预防-诊断-治疗一体的疾病整体管理模式。  

Objectives of Study:

We have attempted to independently develop a semi-quantitative musculoskeletal ultrasound scoring system for gout and hyperuricemia to provide a new tool for accurate assessment of joint lesions. Apply musculoskeletal ultrasound morphology to assess uric acid load in patients with gout and hyperuricemia, provide a basis for disease diagnosis and uric acid-lowering therapy, and promote the accuracy and compliance rate of gout diagnosis and uric acid-lowering therapy. We will fully apply musculoskeletal ultrasound to monitor the whole course of patients with gout and hyperuricemia, improve the efficiency of diagnosis and treatment, and build a holistic management model of prevention, diagnosis and treatment.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

痛风组纳入标准:①符合上诉诊断标准;②年龄≥18岁;③至少一个月未进行降尿酸治疗;④签署知情同意书。 高尿酸血症组纳入标准:①非同日2次空腹血尿酸(SUA)≥420μmol/L;②年龄≥18岁;③无痛风病史;④签署知情同意书。

Inclusion criteria

Inclusion criteria for the gout group: ① meeting the diagnostic criteria for appeal; ② age ≥18 years; ③ no uric acid-lowering treatment for at least one month; ④ signing the informed consent form. Inclusion criteria for the hyperuricemia group: ① 2 fasting blood uric acid (SUA) ≥ 420 μmol/L on non-same day; ② age ≥ 18 years; ③ no history of gout; ④ sign the informed consent form.

排除标准:

①无症状高尿酸血症患者;②合并其它炎症性关节炎或晶体沉积性关节炎的患者(包括类风湿关节炎、反应性关节炎、银屑病关节炎、脊柱关节炎等);③不适合进行降尿酸治疗的患者(由于肿瘤放疗、化疗、血液病、服用某些药物导致的继发性痛风;严重肝肾功能不全;严重心、肺、脑血管疾病及恶性肿瘤);④精神病等无法合作患者。

Exclusion criteria:

(1) Patients with asymptomatic hyperuricemia; (2) Patients with other combined inflammatory arthritis or crystal deposition arthritis (including rheumatoid arthritis, reactive arthritis, psoriatic arthritis, spinal arthritis, etc.); (3) Patients who are not suitable for uric acid-lowering therapy (secondary gout due to tumor radiotherapy, chemotherapy, hematological diseases, taking certain drugs; severe liver and kidney insufficiency; severe cardiac, pulmonary, cerebrovascular diseases and malignant tumors); (4) Patients who are unable to cooperate such as psychiatric diseases.

研究实施时间:

Study execute time:

From 2023-03-21 00:00:00 To 2024-11-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-03-21 00:00:00 To 2024-11-30 00:00:00

干预措施:

Interventions:

组别:

痛风组

样本量:

90

Group:

Group of gout

Sample size:

干预措施:

降尿酸治疗

干预措施代码:

Intervention:

urate-lowering therapy

Intervention code:

组别:

高尿酸血症组

样本量:

100

Group:

Group of hyperuricemia

Sample size:

干预措施:

降尿酸治疗

干预措施代码:

Intervention:

urate-lowering therapy

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆市 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆市中医院 

单位级别:

三甲 

Institution
hospital:

Chongqing Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

血尿酸

指标类型:

主要指标

Outcome:

Blood uric acid

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肌骨超声

指标类型:

主要指标

Outcome:

Musculoskeletal ultrasound

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

痛风疾病活动度评分

指标类型:

主要指标

Outcome:

Gout Activity Score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

临床资料

指标类型:

次要指标

Outcome:

Clinical data

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究者按研究对象入组时间顺序编号

Randomization Procedure (please state who generates the random number sequence and by what method):

Researchers numbered the study subjects in chronological order of enrollment

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2024年12月,ResMan (www.medresman.org.cn)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

December 2024 ResMan (www.medresman.org.cn)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-05-23 08:44:32